Ad
related to: benlysta glaxo- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261
Search results
Results from the WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
GlaxoSmithKline absorbed a pipeline partner with a. ... The partnership's Benlysta was the first lupus treatment to make it to market over 50 years. Approved in 2011, the drug brought in $52 ...
Pharmaceutical maker GlaxoSmithKline will begin a phase 3 clinical trial to judge lupus medication Benlysta's effectiveness in treating patients with ANCA-positive vasculitis. The trial, which ...
GlaxoSmithKline recently acquired lupus drug Benlysta through its purchase of Human Genome Sciences. This acquisition also gives GlaxoSmithKline access to several promising drugs that were in ...
Belimumab (Benlysta) is a monoclonal antibody developed by Human Genome Sciences and GlaxoSmithKline, with significant discovery input by Cambridge Antibody Technology, which specifically recognizes and inhibits the biological activity of B-Lymphocyte stimulator (BLyS) and is in clinical trials for treatment of Systemic lupus erythematosus and ...
Benlysta (belimumab) Betnovate (betamethasone valerate) Blenrep (belantamab mafodotin) Breo (fluticasone furoate, vilanterol) Ceftin (cefuroxime axetil) Combodart (dutasteride / tamsulosin hydrochloride) Cutivate (fluticasone propionate) Daraprim (pyrimethamine) Dectova (zanamivir) Dermovate (clobetasol propionate) Duodart (dutasteride ...
Slow and steady might win the race, but it isn't a way to keep biotech investors' interest. As we approach a year after GlaxoSmithKline (NYS: GSK) and Human Genome Sciences' (NAS: HGSI) Benlysta ...
In July 2012, Human Genome Sciences was purchased by Glaxo SmithKline for $3.6 billion. In addition to Benlysta and Abthrax, the purchase gave Glaxo SmithKline exclusive rights to Albiglutide for the treatment of diabetes, and Darapladib for the treatment of coronary artery disease, both were in late stage clinical trials.
Ad
related to: benlysta glaxo- 109 S High St #100, Columbus, OH · Directions · (614) 224-4261